Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT
GRANTING OF A LOAN BY A BANK TO A SUBSIDIARY OF THE COMPANY

This announcement is a voluntary announcement made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 9 September 2025, Pengbo (Hainan) Medical Technology Co., Ltd.# (鵬博(海南)硼中子醫療科技有限公司) ("**Pengbo (Hainan)**") (a company established in the People's Republic of China (the "**PRC**") with limited liability and an indirect wholly-owned subsidiary of the Company as at the date of this announcement) (as borrower) entered into a loan contract with Hainan Rural Commercial Bank Co., Ltd. Qionghai Sub-Branch# (海南農村商業銀行股份有限公司瓊海支行) (as lender) (the "**Lender**"), pursuant to which the Lender agrees to provide Pengbo (Hainan) with a loan in the principal amount of up to RMB180 million (the "**Loan**").

Other details of the Loan are summarised as follows:

Purpose of the Loan	:	For the construction of Boron Neutron Capture Therapy ("**BNCT**") Cancer Treatment Centre ("**BNCT Centre**") project in the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Free Trade Port of the PRC ("**Boao Lecheng Pilot Zone**"), and the replacement of the borrowing between Pengbo (Hainan) and Agricultural Bank of China Limited Qionghai Sub-Branch# (中國農業銀行股份有限公司瓊海市支行) with a balance of approximately RMB20 million as at 31 August 2025.

Term of the Loan	:	10 years. The Loan will be drawn down in instalments (each instalment subject to different drawdown conditions) and has to be repaid in instalments in accordance with the agreed schedule.
Interest	:	4.6% per annum (fixed rate)
Security	:	(1) Pledge of the land use right of a parcel of land located in the Boao Lecheng Pilot Zone under the name of Pengbo (Hainan), the construction-in-progress on the site, and BNCT medical equipment; (2) A company established in the PRC with limited liability (an independent third party) (the "**Third Party Guarantor**") has provided a joint and several guarantee for RMB100 million of the Loan; (3) Mr. Liu Xiaolin (chairman of the Board and an executive Director and a controlling shareholder of the Company) and the Company have provided a joint and several guarantee for the Loan; and (4) Pledge of 100% of the equity interest in Pengbo (Hainan) (if the RMB100 million guaranteed by the Third Party Guarantor is repaid and its joint and several guarantee is released in the future)
Counter-guarantee	:	In view of the security guarantee provided by the Third Party Guarantor for the Loan, the Company will provide a joint and several guarantee to the Third Party Guarantor, and the direct holding company of Pengbo (Hainan) will pledge 100% of the equity interest in Pengbo (Hainan) to the Third Party Guarantor as a counter-guarantee.

The Loan will provide further support for the construction of the BNCT Centre, striving for its opening and commencement of operations at the end of 2025, in order to provide cancer patients in need with BNCT services. Leveraging supportive policies in the Boao Lecheng Pilot Zone and the centre as a showcase, the Group aims to develop and build a network of BNCT Centres across the PRC in the future, develop franchise hospitals, to create more revenue.

All the terms of the Loan and the security and the counter-guarantee provided by the Group have been arrived at after arm's length negotiations among the parties. The Directors are of the view that the terms are fair and reasonable and in the interests of the shareholders of the Company as a whole. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, the Lender, the Third Party Guarantor, and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons. The Loan and the security and the counter-guarantee provided by the Group as well as the joint and several guarantee provided by Mr. Liu Xiaolin are not subject to the notification and announcement requirements under Chapter 19 or Chapter 20 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

For identification purposes only

By order of the Board
China Biotech Services Holdings Limited
Chairman and Executive Director
Liu Xiaolin

Hong Kong, 11 September 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.